Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) Research & Development (2020 - 2026)

Edgewise Therapeutics has reported Research & Development over the past 7 years, most recently at $42.7 million for Q1 2026.

  • Quarterly results put Research & Development at $42.7 million for Q1 2026, up 16.04% from a year ago — trailing twelve months through Mar 2026 was $157.3 million (up 15.62% YoY), and the annual figure for FY2025 was $151.4 million, up 19.24%.
  • Research & Development reached $42.7 million in Q1 2026 per EWTX's latest filing, down from $43.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $43.6 million in Q4 2025 and bottomed at $11.1 million in Q1 2022.
  • Median Research & Development over the past 5 years was $27.7 million (2024), compared with a mean of $27.4 million.
  • The largest annual shift saw Research & Development surged 107.54% in 2022 before it rose 9.38% in 2025.
  • Over 5 years, Research & Development stood at $16.6 million in 2022, then surged by 66.65% to $27.7 million in 2023, then surged by 31.38% to $36.4 million in 2024, then grew by 19.86% to $43.6 million in 2025, then decreased by 2.16% to $42.7 million in 2026.
  • Business Quant data shows Research & Development for EWTX at $42.7 million in Q1 2026, $43.6 million in Q4 2025, and $37.5 million in Q3 2025.